Nektar Therapeutics (NKTR) Accumulated Expenses (2010 - 2026)

Nektar Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses changed 0.36% year-over-year to $5.0 million in Q1 2026; TTM through Mar 2026 was $5.0 million, a 0.36% change from a year earlier, with the FY2025 full-year figure at $22.3 million, down 25.69% from the prior year.
• Accumulated Expenses slipped to $5.0 million in Q1 2026 per NKTR's latest filing, from $22.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $37.4 million in Q1 2023 and bottomed at $5.0 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $24.4 million (2022), against an average of $21.3 million.
• Across the five-year window, Accumulated Expenses sank 84.81% in 2023 and soared 439.74% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $36.6 million in 2022, then sank by 84.81% to $5.6 million in 2023, then surged by 439.74% to $30.0 million in 2024, then decreased by 25.69% to $22.3 million in 2025, then slumped by 77.51% to $5.0 million in 2026.
• Per Business Quant, the three latest NKTR Accumulated Expenses figures stand at $5.0 million (Q1 2026), $22.3 million (Q4 2025), and $8.6 million (Q3 2025).